GCP guidelines for safety reporting in clinical trials state that:
- All serious adverse events (SAEs) should be reported immediately to the sponsor
- Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor
- For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).
